Global Drug-Eluting Stents Market to Reach $11.7 Billion by 2030
NEW YORK, Feb. 14, 2023 /PRNewswire/ -- The global economy is at a critical crossroads with a number of interlocking challenges and crises running in parallel. The uncertainty around how Russia`s war on Ukraine will play out this year and the war`s role in creating global instability means that the trouble on the inflation front is not over yet. Food and fuel inflation will remain a persistent economic problem. Higher retail inflation will impact consumer confidence and spending. As governments combat inflation by raising interest rates, new job creation will slowdown and impact economic activity and growth. Lower capital expenditure is in the offing as companies go slow on investments, held back by inflation worries and weaker demand. With slower growth and high inflation, developed markets seem primed to enter into a recession. Fears of new COVID outbreaks and China's already uncertain post-pandemic path poses a real risk of the world experiencing more acute supply chain pain and manufacturing disruptions this year. Volatile financial markets, growing trade tensions, stricter regulatory environment and pressure to mainstream climate change into economic decisions will compound the complexity of challenges faced. Year 2023 is expected to be tough year for most markets, investors and consumers. Nevertheless, there is always opportunity for businesses and their leaders who can chart a path forward with resilience and adaptability.
Read the full report: https://www.reportlinker.com/p05443570/?utm_source=PRN
Global Drug-Eluting Stents Market to Reach $11.7 Billion by 2030
In the changed post COVID-19 business landscape, the global market for Drug-Eluting Stents estimated at US$7.3 Billion in the year 2022, is projected to reach a revised size of US$11.7 Billion by 2030, growing at aCAGR of 6% over the period 2022-2030. Polymer-Free, one of the segments analyzed in the report, is projected to record 6.3% CAGR and reach US$7.9 Billion by the end of the analysis period. Taking into account the ongoing post pandemic recovery, growth in the Polymer-based segment is readjusted to a revised 5.5% CAGR for the next 8-year period.
The U.S. Market is Estimated at $2 Billion, While China is Forecast to Grow at 9.9% CAGR
The Drug-Eluting Stents market in the U.S. is estimated at US$2 Billion in the year 2022. China, the world`s second largest economy, is forecast to reach a projected market size of US$2.6 Billion by the year 2030 trailing a CAGR of 9.9% over the analysis period 2022 to 2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 2.2% and 6.4% respectively over the 2022-2030 period. Within Europe, Germany is forecast to grow at approximately 3.4% CAGR.
Select Competitors (Total 33 Featured)
- Abbott Laboratories
- AlviMedica
- Arterius Limited
- Biotronik SE
- Boston Scientific Corporation
- Cook Medical
- Medtronic plc
- STENTYS SA
- Terumo Corporation
Read the full report: https://www.reportlinker.com/p05443570/?utm_source=PRN
I. METHODOLOGY
II. EXECUTIVE SUMMARY
1. MARKET OVERVIEW
Influencer Market Insights
World Market Trajectories
Coronary Stents Market - A Prelude
Recent Market Activity
Competitive Scenario
J&J Exit from DES Market Improves Prospects for Competitors
Evolution of the Drug-Eluting Stent
Evolution of Drug-Eluting Stents (DES) Over the Years
Comparative Analysis of Drug-Eluting Stents in Terms of
Physical Parameters
Bioabsorbable Stents
New Stents with Biodegradable Polymers
Completely Bioresorbable Scaffolds: Potential Game-Changer
Noteworthy Clinical Studies and Innovations
Study Proves Efficacy of Very Thin Strut DES On Par with
Durable Polymer Stents
Drug-Eluting Stents and Drug-Coated Balloons for Non-Coronary
Indications
DES for Large Sized Arteries
Addressing the Unmet Challenges in Patients with Diabetes
Biosensors Commercializes BMX-J DES System
SLENDER DES Set to Downsize the Future of Interventional
Cardiology
Other Novel DES Launches
Researchers at University of Strathclyde Evaluate VAN 10-4
Small Molecule
DES Safe for Vein Grafts Procedures
Drug-Eluting Stents - Global Key Competitors Percentage Market
Share in 2022 (E)
Competitive Market Presence - Strong/Active/Niche/Trivial for
Players Worldwide in 2022 (E)
Impact of Covid-19 and a Looming Global Recession
2. FOCUS ON SELECT PLAYERS
3. MARKET TRENDS & DRIVERS
Key Market Drivers & Restraints
Aging - A Key Market Driver
Global Aging Population Demographic Statistics: Key Opportunity
Indicator
High Diabetes Incidence Worldwide Drives Demand for Cardiac
Surgery and Stents
4. GLOBAL MARKET PERSPECTIVE
Table 1: World Recent Past, Current & Future Analysis for
Drug-Eluting Stents by Geographic Region - USA, Canada, Japan,
China, Europe, Asia-Pacific, Latin America, Middle East and
Africa Markets - Independent Analysis of Annual Sales in US$
Million for Years 2022 through 2030 and % CAGR
Table 2: World Historic Review for Drug-Eluting Stents by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2014 through 2021 and % CAGR
Table 3: World 16-Year Perspective for Drug-Eluting Stents by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa Markets for Years 2014, 2023 & 2030
Table 4: World Recent Past, Current & Future Analysis for
Polymer-Free by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific, Latin America, Middle East and Africa
Markets - Independent Analysis of Annual Sales in US$ Million
for Years 2022 through 2030 and % CAGR
Table 5: World Historic Review for Polymer-Free by Geographic
Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin
America, Middle East and Africa Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2014 through 2021 and
% CAGR
Table 6: World 16-Year Perspective for Polymer-Free by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2014, 2023 & 2030
Table 7: World Recent Past, Current & Future Analysis for
Polymer-based by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific, Latin America, Middle East and Africa
Markets - Independent Analysis of Annual Sales in US$ Million
for Years 2022 through 2030 and % CAGR
Table 8: World Historic Review for Polymer-based by Geographic
Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin
America, Middle East and Africa Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2014 through 2021 and
% CAGR
Table 9: World 16-Year Perspective for Polymer-based by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2014, 2023 & 2030
Table 10: World Recent Past, Current & Future Analysis for
Coronary Artery Disease by Geographic Region - USA, Canada,
Japan, China, Europe, Asia-Pacific, Latin America, Middle East
and Africa Markets - Independent Analysis of Annual Sales in
US$ Million for Years 2022 through 2030 and % CAGR
Table 11: World Historic Review for Coronary Artery Disease by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2014 through 2021 and % CAGR
Table 12: World 16-Year Perspective for Coronary Artery Disease
by Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2014, 2023 & 2030
Table 13: World Recent Past, Current & Future Analysis for
Peripheral Artery Disease by Geographic Region - USA, Canada,
Japan, China, Europe, Asia-Pacific, Latin America, Middle East
and Africa Markets - Independent Analysis of Annual Sales in
US$ Million for Years 2022 through 2030 and % CAGR
Table 14: World Historic Review for Peripheral Artery Disease
by Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2014 through 2021 and % CAGR
Table 15: World 16-Year Perspective for Peripheral Artery
Disease by Geographic Region - Percentage Breakdown of Value
Sales for USA, Canada, Japan, China, Europe, Asia-Pacific,
Latin America, Middle East and Africa for Years 2014, 2023 &
2030
Table 16: World Recent Past, Current & Future Analysis for
Cardiology Centers by Geographic Region - USA, Canada, Japan,
China, Europe, Asia-Pacific, Latin America, Middle East and
Africa Markets - Independent Analysis of Annual Sales in US$
Million for Years 2022 through 2030 and % CAGR
Table 17: World Historic Review for Cardiology Centers by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2014 through 2021 and % CAGR
Table 18: World 16-Year Perspective for Cardiology Centers by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2014, 2023 & 2030
Table 19: World Recent Past, Current & Future Analysis for
Hospitals by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific, Latin America, Middle East and Africa
Markets - Independent Analysis of Annual Sales in US$ Million
for Years 2022 through 2030 and % CAGR
Table 20: World Historic Review for Hospitals by Geographic
Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin
America, Middle East and Africa Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2014 through 2021 and
% CAGR
Table 21: World 16-Year Perspective for Hospitals by Geographic
Region - Percentage Breakdown of Value Sales for USA, Canada,
Japan, China, Europe, Asia-Pacific, Latin America, Middle East
and Africa for Years 2014, 2023 & 2030
Table 22: World Recent Past, Current & Future Analysis for
Ambulatory Surgery Centers by Geographic Region - USA, Canada,
Japan, China, Europe, Asia-Pacific, Latin America, Middle East
and Africa Markets - Independent Analysis of Annual Sales in
US$ Million for Years 2022 through 2030 and % CAGR
Table 23: World Historic Review for Ambulatory Surgery Centers
by Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2014 through 2021 and % CAGR
Table 24: World 16-Year Perspective for Ambulatory Surgery
Centers by Geographic Region - Percentage Breakdown of Value
Sales for USA, Canada, Japan, China, Europe, Asia-Pacific,
Latin America, Middle East and Africa for Years 2014, 2023 &
2030
Table 25: World Drug-Eluting Stents Market Analysis of Annual
Sales in US$ Million for Years 2014 through 2030
III. MARKET ANALYSIS
UNITED STATES
Drug-Eluting Stents Market Presence - Strong/Active/Niche/
Trivial - Key Competitors in the United States for 2023 (E)
Table 26: USA Recent Past, Current & Future Analysis for
Drug-Eluting Stents by Coating - Polymer-Free and Polymer-based -
Independent Analysis of Annual Sales in US$ Million for the
Years 2022 through 2030 and % CAGR
Table 27: USA Historic Review for Drug-Eluting Stents by
Coating - Polymer-Free and Polymer-based Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2014 through
2021 and % CAGR
Table 28: USA 16-Year Perspective for Drug-Eluting Stents by
Coating - Percentage Breakdown of Value Sales for Polymer-Free
and Polymer-based for the Years 2014, 2023 & 2030
Table 29: USA Recent Past, Current & Future Analysis for
Drug-Eluting Stents by Application - Coronary Artery Disease
and Peripheral Artery Disease - Independent Analysis of Annual
Sales in US$ Million for the Years 2022 through 2030 and % CAGR
Table 30: USA Historic Review for Drug-Eluting Stents by
Application - Coronary Artery Disease and Peripheral Artery
Disease Markets - Independent Analysis of Annual Sales in US$
Million for Years 2014 through 2021 and % CAGR
Table 31: USA 16-Year Perspective for Drug-Eluting Stents by
Application - Percentage Breakdown of Value Sales for Coronary
Artery Disease and Peripheral Artery Disease for the Years
2014, 2023 & 2030
Table 32: USA Recent Past, Current & Future Analysis for
Drug-Eluting Stents by End-Use - Cardiology Centers, Ambulatory
Surgery Centers and Hospitals - Independent Analysis of Annual
Sales in US$ Million for the Years 2022 through 2030 and % CAGR
Table 33: USA Historic Review for Drug-Eluting Stents by
End-Use - Cardiology Centers, Ambulatory Surgery Centers and
Hospitals Markets - Independent Analysis of Annual Sales in US$
Million for Years 2014 through 2021 and % CAGR
Table 34: USA 16-Year Perspective for Drug-Eluting Stents by
End-Use - Percentage Breakdown of Value Sales for Cardiology
Centers, Ambulatory Surgery Centers and Hospitals for the Years
2014, 2023 & 2030
CANADA
Table 35: Canada Recent Past, Current & Future Analysis for
Drug-Eluting Stents by Coating - Polymer-Free and Polymer-based -
Independent Analysis of Annual Sales in US$ Million for the
Years 2022 through 2030 and % CAGR
Table 36: Canada Historic Review for Drug-Eluting Stents by
Coating - Polymer-Free and Polymer-based Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2014 through
2021 and % CAGR
Table 37: Canada 16-Year Perspective for Drug-Eluting Stents by
Coating - Percentage Breakdown of Value Sales for Polymer-Free
and Polymer-based for the Years 2014, 2023 & 2030
Table 38: Canada Recent Past, Current & Future Analysis for
Drug-Eluting Stents by Application - Coronary Artery Disease
and Peripheral Artery Disease - Independent Analysis of Annual
Sales in US$ Million for the Years 2022 through 2030 and % CAGR
Table 39: Canada Historic Review for Drug-Eluting Stents by
Application - Coronary Artery Disease and Peripheral Artery
Disease Markets - Independent Analysis of Annual Sales in US$
Million for Years 2014 through 2021 and % CAGR
Table 40: Canada 16-Year Perspective for Drug-Eluting Stents by
Application - Percentage Breakdown of Value Sales for Coronary
Artery Disease and Peripheral Artery Disease for the Years
2014, 2023 & 2030
Table 41: Canada Recent Past, Current & Future Analysis for
Drug-Eluting Stents by End-Use - Cardiology Centers, Ambulatory
Surgery Centers and Hospitals - Independent Analysis of Annual
Sales in US$ Million for the Years 2022 through 2030 and % CAGR
Table 42: Canada Historic Review for Drug-Eluting Stents by
End-Use - Cardiology Centers, Ambulatory Surgery Centers and
Hospitals Markets - Independent Analysis of Annual Sales in US$
Million for Years 2014 through 2021 and % CAGR
Table 43: Canada 16-Year Perspective for Drug-Eluting Stents by
End-Use - Percentage Breakdown of Value Sales for Cardiology
Centers, Ambulatory Surgery Centers and Hospitals for the Years
2014, 2023 & 2030
JAPAN
Drug-Eluting Stents Market Presence - Strong/Active/Niche/
Trivial - Key Competitors in Japan for 2023 (E)
Table 44: Japan Recent Past, Current & Future Analysis for
Drug-Eluting Stents by Coating - Polymer-Free and Polymer-based -
Independent Analysis of Annual Sales in US$ Million for the
Years 2022 through 2030 and % CAGR
Table 45: Japan Historic Review for Drug-Eluting Stents by
Coating - Polymer-Free and Polymer-based Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2014 through
2021 and % CAGR
Table 46: Japan 16-Year Perspective for Drug-Eluting Stents by
Coating - Percentage Breakdown of Value Sales for Polymer-Free
and Polymer-based for the Years 2014, 2023 & 2030
Table 47: Japan Recent Past, Current & Future Analysis for
Drug-Eluting Stents by Application - Coronary Artery Disease
and Peripheral Artery Disease - Independent Analysis of Annual
Sales in US$ Million for the Years 2022 through 2030 and % CAGR
Table 48: Japan Historic Review for Drug-Eluting Stents by
Application - Coronary Artery Disease and Peripheral Artery
Disease Markets - Independent Analysis of Annual Sales in US$
Million for Years 2014 through 2021 and % CAGR
Table 49: Japan 16-Year Perspective for Drug-Eluting Stents by
Application - Percentage Breakdown of Value Sales for Coronary
Artery Disease and Peripheral Artery Disease for the Years
2014, 2023 & 2030
Table 50: Japan Recent Past, Current & Future Analysis for
Drug-Eluting Stents by End-Use - Cardiology Centers, Ambulatory
Surgery Centers and Hospitals - Independent Analysis of Annual
Sales in US$ Million for the Years 2022 through 2030 and % CAGR
Table 51: Japan Historic Review for Drug-Eluting Stents by
End-Use - Cardiology Centers, Ambulatory Surgery Centers and
Hospitals Markets - Independent Analysis of Annual Sales in US$
Million for Years 2014 through 2021 and % CAGR
Table 52: Japan 16-Year Perspective for Drug-Eluting Stents by
End-Use - Percentage Breakdown of Value Sales for Cardiology
Centers, Ambulatory Surgery Centers and Hospitals for the Years
2014, 2023 & 2030
CHINA
Drug-Eluting Stents Market Presence - Strong/Active/Niche/
Trivial - Key Competitors in China for 2023 (E)
Table 53: China Recent Past, Current & Future Analysis for
Drug-Eluting Stents by Coating - Polymer-Free and Polymer-based -
Independent Analysis of Annual Sales in US$ Million for the
Years 2022 through 2030 and % CAGR
Table 54: China Historic Review for Drug-Eluting Stents by
Coating - Polymer-Free and Polymer-based Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2014 through
2021 and % CAGR
Table 55: China 16-Year Perspective for Drug-Eluting Stents by
Coating - Percentage Breakdown of Value Sales for Polymer-Free
and Polymer-based for the Years 2014, 2023 & 2030
Table 56: China Recent Past, Current & Future Analysis for
Drug-Eluting Stents by Application - Coronary Artery Disease
and Peripheral Artery Disease - Independent Analysis of Annual
Sales in US$ Million for the Years 2022 through 2030 and % CAGR
Table 57: China Historic Review for Drug-Eluting Stents by
Application - Coronary Artery Disease and Peripheral Artery
Disease Markets - Independent Analysis of Annual Sales in US$
Million for Years 2014 through 2021 and % CAGR
Table 58: China 16-Year Perspective for Drug-Eluting Stents by
Application - Percentage Breakdown of Value Sales for Coronary
Artery Disease and Peripheral Artery Disease for the Years
2014, 2023 & 2030
Table 59: China Recent Past, Current & Future Analysis for
Drug-Eluting Stents by End-Use - Cardiology Centers, Ambulatory
Surgery Centers and Hospitals - Independent Analysis of Annual
Sales in US$ Million for the Years 2022 through 2030 and % CAGR
Table 60: China Historic Review for Drug-Eluting Stents by
End-Use - Cardiology Centers, Ambulatory Surgery Centers and
Hospitals Markets - Independent Analysis of Annual Sales in US$
Million for Years 2014 through 2021 and % CAGR
Table 61: China 16-Year Perspective for Drug-Eluting Stents by
End-Use - Percentage Breakdown of Value Sales for Cardiology
Centers, Ambulatory Surgery Centers and Hospitals for the Years
2014, 2023 & 2030
EUROPE
Drug-Eluting Stents Market Presence - Strong/Active/Niche/
Trivial - Key Competitors in Europe for 2023 (E)
Table 62: Europe Recent Past, Current & Future Analysis for
Drug-Eluting Stents by Geographic Region - France, Germany,
Italy, UK, Spain, Russia and Rest of Europe Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2022 through 2030 and % CAGR
Table 63: Europe Historic Review for Drug-Eluting Stents by
Geographic Region - France, Germany, Italy, UK, Spain, Russia
and Rest of Europe Markets - Independent Analysis of Annual
Sales in US$ Million for Years 2014 through 2021 and % CAGR
Table 64: Europe 16-Year Perspective for Drug-Eluting Stents by
Geographic Region - Percentage Breakdown of Value Sales for
France, Germany, Italy, UK, Spain, Russia and Rest of Europe
Markets for Years 2014, 2023 & 2030
Table 65: Europe Recent Past, Current & Future Analysis for
Drug-Eluting Stents by Coating - Polymer-Free and Polymer-based -
Independent Analysis of Annual Sales in US$ Million for the
Years 2022 through 2030 and % CAGR
Table 66: Europe Historic Review for Drug-Eluting Stents by
Coating - Polymer-Free and Polymer-based Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2014 through
2021 and % CAGR
Table 67: Europe 16-Year Perspective for Drug-Eluting Stents by
Coating - Percentage Breakdown of Value Sales for Polymer-Free
and Polymer-based for the Years 2014, 2023 & 2030
Table 68: Europe Recent Past, Current & Future Analysis for
Drug-Eluting Stents by Application - Coronary Artery Disease
and Peripheral Artery Disease - Independent Analysis of Annual
Sales in US$ Million for the Years 2022 through 2030 and % CAGR
Table 69: Europe Historic Review for Drug-Eluting Stents by
Application - Coronary Artery Disease and Peripheral Artery
Disease Markets - Independent Analysis of Annual Sales in US$
Million for Years 2014 through 2021 and % CAGR
Table 70: Europe 16-Year Perspective for Drug-Eluting Stents by
Application - Percentage Breakdown of Value Sales for Coronary
Artery Disease and Peripheral Artery Disease for the Years
2014, 2023 & 2030
Table 71: Europe Recent Past, Current & Future Analysis for
Drug-Eluting Stents by End-Use - Cardiology Centers, Ambulatory
Surgery Centers and Hospitals - Independent Analysis of Annual
Sales in US$ Million for the Years 2022 through 2030 and % CAGR
Table 72: Europe Historic Review for Drug-Eluting Stents by
End-Use - Cardiology Centers, Ambulatory Surgery Centers and
Hospitals Markets - Independent Analysis of Annual Sales in US$
Million for Years 2014 through 2021 and % CAGR
Table 73: Europe 16-Year Perspective for Drug-Eluting Stents by
End-Use - Percentage Breakdown of Value Sales for Cardiology
Centers, Ambulatory Surgery Centers and Hospitals for the Years
2014, 2023 & 2030
FRANCE
Drug-Eluting Stents Market Presence - Strong/Active/Niche/
Trivial - Key Competitors in France for 2023 (E)
Table 74: France Recent Past, Current & Future Analysis for
Drug-Eluting Stents by Coating - Polymer-Free and Polymer-based -
Independent Analysis of Annual Sales in US$ Million for the
Years 2022 through 2030 and % CAGR
Table 75: France Historic Review for Drug-Eluting Stents by
Coating - Polymer-Free and Polymer-based Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2014 through
2021 and % CAGR
Table 76: France 16-Year Perspective for Drug-Eluting Stents by
Coating - Percentage Breakdown of Value Sales for Polymer-Free
and Polymer-based for the Years 2014, 2023 & 2030
Table 77: France Recent Past, Current & Future Analysis for
Drug-Eluting Stents by Application - Coronary Artery Disease
and Peripheral Artery Disease - Independent Analysis of Annual
Sales in US$ Million for the Years 2022 through 2030 and % CAGR
Table 78: France Historic Review for Drug-Eluting Stents by
Application - Coronary Artery Disease and Peripheral Artery
Disease Markets - Independent Analysis of Annual Sales in US$
Million for Years 2014 through 2021 and % CAGR
Table 79: France 16-Year Perspective for Drug-Eluting Stents by
Application - Percentage Breakdown of Value Sales for Coronary
Artery Disease and Peripheral Artery Disease for the Years
2014, 2023 & 2030
Table 80: France Recent Past, Current & Future Analysis for
Drug-Eluting Stents by End-Use - Cardiology Centers, Ambulatory
Surgery Centers and Hospitals - Independent Analysis of Annual
Sales in US$ Million for the Years 2022 through 2030 and % CAGR
Table 81: France Historic Review for Drug-Eluting Stents by
End-Use - Cardiology Centers, Ambulatory Surgery Centers and
Hospitals Markets - Independent Analysis of Annual Sales in US$
Million for Years 2014 through 2021 and % CAGR
Table 82: France 16-Year Perspective for Drug-Eluting Stents by
End-Use - Percentage Breakdown of Value Sales for Cardiology
Centers, Ambulatory Surgery Centers and Hospitals for the Years
2014, 2023 & 2030
GERMANY
Drug-Eluting Stents Market Presence - Strong/Active/Niche/
Trivial - Key Competitors in Germany for 2023 (E)
Table 83: Germany Recent Past, Current & Future Analysis for
Drug-Eluting Stents by Coating - Polymer-Free and Polymer-based -
Independent Analysis of Annual Sales in US$ Million for the
Years 2022 through 2030 and % CAGR
Table 84: Germany Historic Review for Drug-Eluting Stents by
Coating - Polymer-Free and Polymer-based Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2014 through
2021 and % CAGR
Table 85: Germany 16-Year Perspective for Drug-Eluting Stents
by Coating - Percentage Breakdown of Value Sales for
Polymer-Free and Polymer-based for the Years 2014, 2023 & 2030
Table 86: Germany Recent Past, Current & Future Analysis for
Drug-Eluting Stents by Application - Coronary Artery Disease
and Peripheral Artery Disease - Independent Analysis of Annual
Sales in US$ Million for the Years 2022 through 2030 and % CAGR
Table 87: Germany Historic Review for Drug-Eluting Stents by
Application - Coronary Artery Disease and Peripheral Artery
Disease Markets - Independent Analysis of Annual Sales in US$
Million for Years 2014 through 2021 and % CAGR
Table 88: Germany 16-Year Perspective for Drug-Eluting Stents
by Application - Percentage Breakdown of Value Sales for
Coronary Artery Disease and Peripheral Artery Disease for the
Years 2014, 2023 & 2030
Table 89: Germany Recent Past, Current & Future Analysis for
Drug-Eluting Stents by End-Use - Cardiology Centers, Ambulatory
Surgery Centers and Hospitals - Independent Analysis of Annual
Sales in US$ Million for the Years 2022 through 2030 and % CAGR
Table 90: Germany Historic Review for Drug-Eluting Stents by
End-Use - Cardiology Centers, Ambulatory Surgery Centers and
Hospitals Markets - Independent Analysis of Annual Sales in US$
Million for Years 2014 through 2021 and % CAGR
Table 91: Germany 16-Year Perspective for Drug-Eluting Stents
by End-Use - Percentage Breakdown of Value Sales for Cardiology
Centers, Ambulatory Surgery Centers and Hospitals for the Years
2014, 2023 & 2030
ITALY
Table 92: Italy Recent Past, Current & Future Analysis for
Drug-Eluting Stents by Coating - Polymer-Free and Polymer-based -
Independent Analysis of Annual Sales in US$ Million for the
Years 2022 through 2030 and % CAGR
Table 93: Italy Historic Review for Drug-Eluting Stents by
Coating - Polymer-Free and Polymer-based Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2014 through
2021 and % CAGR
Table 94: Italy 16-Year Perspective for Drug-Eluting Stents by
Coating - Percentage Breakdown of Value Sales for Polymer-Free
and Polymer-based for the Years 2014, 2023 & 2030
Table 95: Italy Recent Past, Current & Future Analysis for
Drug-Eluting Stents by Application - Coronary Artery Disease
and Peripheral Artery Disease - Independent Analysis of Annual
Sales in US$ Million for the Years 2022 through 2030 and % CAGR
Table 96: Italy Historic Review for Drug-Eluting Stents by
Application - Coronary Artery Disease and Peripheral Artery
Disease Markets - Independent Analysis of Annual Sales in US$
Million for Years 2014 through 2021 and % CAGR
Table 97: Italy 16-Year Perspective for Drug-Eluting Stents by
Application - Percentage Breakdown of Value Sales for Coronary
Artery Disease and Peripheral Artery Disease for the Years
2014, 2023 & 2030
Table 98: Italy Recent Past, Current & Future Analysis for
Drug-Eluting Stents by End-Use - Cardiology Centers, Ambulatory
Surgery Centers and Hospitals - Independent Analysis of Annual
Sales in US$ Million for the Years 2022 through 2030 and % CAGR
Table 99: Italy Historic Review for Drug-Eluting Stents by
End-Use - Cardiology Centers, Ambulatory Surgery Centers and
Hospitals Markets - Independent Analysis of Annual Sales in US$
Million for Years 2014 through 2021 and % CAGR
Table 100: Italy 16-Year Perspective for Drug-Eluting Stents by
End-Use - Percentage Breakdown of Value Sales for Cardiology
Centers, Ambulatory Surgery Centers and Hospitals for the Years
2014, 2023 & 2030
UNITED KINGDOM
Drug-Eluting Stents Market Presence - Strong/Active/Niche/
Trivial - Key Competitors in the United Kingdom for 2023 (E)
Table 101: UK Recent Past, Current & Future Analysis for
Drug-Eluting Stents by Coating - Polymer-Free and Polymer-based -
Independent Analysis of Annual Sales in US$ Million for the
Years 2022 through 2030 and % CAGR
Table 102: UK Historic Review for Drug-Eluting Stents by
Coating - Polymer-Free and Polymer-based Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2014 through
2021 and % CAGR
Table 103: UK 16-Year Perspective for Drug-Eluting Stents by
Coating - Percentage Breakdown of Value Sales for Polymer-Free
and Polymer-based for the Years 2014, 2023 & 2030
Table 104: UK Recent Past, Current & Future Analysis for
Drug-Eluting Stents by Application - Coronary Artery Disease
and Peripheral Artery Disease - Independent Analysis of Annual
Sales in US$ Million for the Years 2022 through 2030 and % CAGR
Table 105: UK Historic Review for Drug-Eluting Stents by
Application - Coronary Artery Disease and Peripheral Artery
Disease Markets - Independent Analysis of Annual Sales in US$
Million for Years 2014 through 2021 and % CAGR
Table 106: UK 16-Year Perspective for Drug-Eluting Stents by
Application - Percentage Breakdown of Value Sales for Coronary
Artery Disease and Peripheral Artery Disease for the Years
2014, 2023 & 2030
Table 107: UK Recent Past, Current & Future Analysis for
Drug-Eluting Stents by End-Use - Cardiology Centers, Ambulatory
Surgery Centers and Hospitals - Independent Analysis of Annual
Sales in US$ Million for the Years 2022 through 2030 and % CAGR
Table 108: UK Historic Review for Drug-Eluting Stents by
End-Use - Cardiology Centers, Ambulatory Surgery Centers and
Hospitals Markets - Independent Analysis of Annual Sales in US$
Million for Years 2014 through 2021 and % CAGR
Table 109: UK 16-Year Perspective for Drug-Eluting Stents by
End-Use - Percentage Breakdown of Value Sales for Cardiology
Centers, Ambulatory Surgery Centers and Hospitals for the Years
2014, 2023 & 2030
SPAIN
Table 110: Spain Recent Past, Current & Future Analysis for
Drug-Eluting Stents by Coating - Polymer-Free and Polymer-based -
Independent Analysis of Annual Sales in US$ Million for the
Years 2022 through 2030 and % CAGR
Table 111: Spain Historic Review for Drug-Eluting Stents by
Coating - Polymer-Free and Polymer-based Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2014 through
2021 and % CAGR
Table 112: Spain 16-Year Perspective for Drug-Eluting Stents by
Coating - Percentage Breakdown of Value Sales for Polymer-Free
and Polymer-based for the Years 2014, 2023 & 2030
Table 113: Spain Recent Past, Current & Future Analysis for
Drug-Eluting Stents by Application - Coronary Artery Disease
and Peripheral Artery Disease - Independent Analysis of Annual
Sales in US$ Million for the Years 2022 through 2030 and % CAGR
Table 114: Spain Historic Review for Drug-Eluting Stents by
Application - Coronary Artery Disease and Peripheral Artery
Disease Markets - Independent Analysis of Annual Sales in US$
Million for Years 2014 through 2021 and % CAGR
Table 115: Spain 16-Year Perspective for Drug-Eluting Stents by
Application - Percentage Breakdown of Value Sales for Coronary
Artery Disease and Peripheral Artery Disease for the Years
2014, 2023 & 2030
Table 116: Spain Recent Past, Current & Future Analysis for
Drug-Eluting Stents by End-Use - Cardiology Centers, Ambulatory
Surgery Centers and Hospitals - Independent Analysis of Annual
Sales in US$ Million for the Years 2022 through 2030 and % CAGR
Table 117: Spain Historic Review for Drug-Eluting Stents by
End-Use - Cardiology Centers, Ambulatory Surgery Centers and
Hospitals Markets - Independent Analysis of Annual Sales in US$
Million for Years 2014 through 2021 and % CAGR
Table 118: Spain 16-Year Perspective for Drug-Eluting Stents by
End-Use - Percentage Breakdown of Value Sales for Cardiology
Centers, Ambulatory Surgery Centers and Hospitals for the Years
2014, 2023 & 2030
RUSSIA
Table 119: Russia Recent Past, Current & Future Analysis for
Drug-Eluting Stents by Coating - Polymer-Free and Polymer-based -
Independent Analysis of Annual Sales in US$ Million for the
Years 2022 through 2030 and % CAGR
Table 120: Russia Historic Review for Drug-Eluting Stents by
Coating - Polymer-Free and Polymer-based Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2014 through
2021 and % CAGR
Table 121: Russia 16-Year Perspective for Drug-Eluting Stents
by Coating - Percentage Breakdown of Value Sales for
Polymer-Free and Polymer-based for the Years 2014, 2023 & 2030
Table 122: Russia Recent Past, Current & Future Analysis for
Drug-Eluting Stents by Application - Coronary Artery Disease
and Peripheral Artery Disease - Independent Analysis of Annual
Sales in US$ Million for the Years 2022 through 2030 and % CAGR
Table 123: Russia Historic Review for Drug-Eluting Stents by
Application - Coronary Artery Disease and Peripheral Artery
Disease Markets - Independent Analysis of Annual Sales in US$
Million for Years 2014 through 2021 and % CAGR
Table 124: Russia 16-Year Perspective for Drug-Eluting Stents
by Application - Percentage Breakdown of Value Sales for
Coronary Artery Disease and Peripheral Artery Disease for the
Years 2014, 2023 & 2030
Table 125: Russia Recent Past, Current & Future Analysis for
Drug-Eluting Stents by End-Use - Cardiology Centers, Ambulatory
Surgery Centers and Hospitals - Independent Analysis of Annual
Sales in US$ Million for the Years 2022 through 2030 and % CAGR
Table 126: Russia Historic Review for Drug-Eluting Stents by
End-Use - Cardiology Centers, Ambulatory Surgery Centers and
Hospitals Markets - Independent Analysis of Annual Sales in US$
Million for Years 2014 through 2021 and % CAGR
Table 127: Russia 16-Year Perspective for Drug-Eluting Stents
by End-Use - Percentage Breakdown of Value Sales for Cardiology
Centers, Ambulatory Surgery Centers and Hospitals for the Years
2014, 2023 & 2030
REST OF EUROPE
Table 128: Rest of Europe Recent Past, Current & Future
Analysis for Drug-Eluting Stents by Coating - Polymer-Free and
Please contact our Customer Support Center to get the complete Table of Contents
Read the full report: https://www.reportlinker.com/p05443570/?utm_source=PRN
About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.
__________________________
Contact Clare: [email protected]
US: (339)-368-6001
Intl: +1 339-368-6001
SOURCE Reportlinker
Share this article